alexa Drugs for the Prevention and Treatment of Cardiac Allograft Vasculopathy

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Drugs for the Prevention and Treatment of Cardiac Allograft Vasculopathy

Cardiac allograft vasculopathy (CAV) of heart transplants is responsible for up to one-third of deaths at 5 years following cardiac transplantation. Risk factors for CAV include both traditional risk factors and immune factors. Drugs used for prevention and treatment of CAV include statins, calcium channel blockers and immunosuppressive agents. This review discusses the currently available drugs for CAV, the evidence behind their use, and future targets of therapy.

Citation: Shuchita Gupta MD (2014) Drugs for the Prevention and Treatment of Cardiac Allograft Vasculopathy. Cardiol Pharmacol 3:123.

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords